4WEB Medical Data Supports TRUSS Implant Tech for Therapeutic Effect

4WEB Medical, a company that develops orthopedic implants using its TRUSS Implant Technology, announced release of a study conducted at the McKay Orthopaedic Research Laboratory, Center for Musculoskeletal Disorders at the University of Pennsylvania.

The study: Therapeutic Implants: Mechanobiologic Enhancement of Osteogenic, Angiogenic, and Myogenic Responses in Human Mesenchymal Stem Cells on 3D-Printed Titanium Truss has been approved for peer reviewed publication in the journal Advanced Healthcare Materials (AHM).

The in vitro study found that orthopedic implants with advanced structural designs stimulate a therapeutic biologic effect. TRUSS Implant Technology was found to provide a synergistic relationship between hierarchical surface roughness and the macro truss architecture.

Compared to surface roughness alone, the delivery of strain through a truss element demonstrated up to a 30% increase in the osteogenic activity in attached cellular material.

“We are extremely pleased with the results of this study,” said 4WEB’s founder and CEO, Jessee Hunt. “The evolution of our Truss Implant Technology continues to gain momentum. The UPENN study demonstrates that the truss implant maintains differentiation as the only therapeutic implant on the market. The structural mechanics of the truss design converts physiologic load into therapeutic strain at the surgical site, amplifying osteogenic activity. This therapeutic effect gives surgeons and their patients the best chance for success by providing ongoing support while biologic fusion takes place. Welcome to the era of therapeutic implants!”

RELATED: Brad Niemann Appointed President at 4WEB Medical

The company intends to build on this research with further studies that focus on reducing high procedural costs related to using BMP and cellular biologics. 4WEB believes the studies will demonstrate therapeutic properties of the TRUSS Implant Technology, in combination with cost-effective biologic graft material, will result in a more cost-effective solution with quicker rates of fusion.

Dr. Andrew Sama, co-chief of HSS Spine in New York commented, “The study conducted on 4WEB’s truss implant by UPENN is the first that I have seen where the implant provides a therapeutic effect independent of chemical influence and beyond passive features such as surface roughness.”